WELCOME TO THE PCPI OFFICIAL WEBSITE
The Presidents of the Chamber of Filipino Drug Manufacturers and Distributors, Inc. (CFDMD), Association of Drug Industries of the Philippines (ADIP), Association of Philippine Manufacturers (APMan) and Filipino Drug Association (FIDA) understood the power of a single voice to advocate the interest of the Filipino pharmaceutical industry in a then foreign-dominated pharmaceutical market. In March 2004, through the resolve of the leaders of these four Filipino Pharmaceutical organizations, the Philippine Chamber of the Pharmaceutical Industry was formed. Its’ Vision of A Competitive Filipino Pharmaceutical Industry and a Mission to Enable the Filipino Pharmaceutical Industry to Lead. Under the stewardship of our leaders and the critical support of its members, PCPI is over 100 Filipino-owned companies strong. More importantly, PCPI is recognized as the “one and sole” voice of the Filipino Pharmaceutical Industry As the sole voice, PCPI proactively engages relevant stakeholders to take action on its advocacies. We are grateful that government and the private sector seek our position on issues relevant to the Philippine Pharmaceutical Industry. We continually bring the Filipino’s interest into the paradigm of those who craft the policies that govern our industry. Confidently, PCPI can state that in the years since its’ birth, Filipino-owned pharmaceutical companies have taken the lead in providing the Filipino people with pharmaceutical products that meet global standards.
MICHAEL FRANCIS A. DELA CRUZ
Founding President
News and Update
PCPI Participates in House Joint Hearing to Strengthen FDA and Improve Medicine Access
18 February 2026 – House of Representatives
​
The Philippine Chamber of the Pharmaceutical Industry, Inc. (PCPI) actively participated in the Joint Public Hearing of the House Committee on Health and the Committee on Revision of Laws on House Resolution No. 550, a measure seeking to strengthen the Food and Drug Administration (FDA) in line with Republic Act No. 9711 (FDA Act of 2009).
Representing PCPI during the hearing were: Ms. Jingle Diola, Vice President for Marketing, Mr. Robert Eugenio, Vice President for Manufacturing, Ms. Marilou Buensuceso, PCPI Board Director
​
The joint hearing marks a critical step toward advancing reforms that will:

-
Modernize the FDA’s regulatory systems
-
Address persistent application and product registration backlogs

-
Strengthen the agency’s institutional and technical capacity

-
Ensure timely access to safe, effective, quality, and affordable medicines for Filipino patients

PCPI recognizes that a strong, efficient, and transparent regulatory system is fundamental to public health protection and national resilience. Regulatory reform is not only about streamlining processes—it is about safeguarding patients, encouraging responsible industry compliance, and ensuring medicine security for the country.
The Chamber commends the House of Representatives for initiating this important dialogue and for acknowledging that regulatory efficiency, transparency, and medicine access are shared national priorities.
As the unified voice of Filipino-owned pharmaceutical manufacturers, PCPI reaffirms its commitment to working collaboratively with lawmakers, regulators, and stakeholders in advancing meaningful reforms that protect patients and strengthen the Philippine healthcare system.